Hypoglycemic Efficacy of Rh-aFGF Variants in Treatment of Diabetes in ZDF Rats
Open Access
- 18 February 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
Abstract
Acidic fibroblast growth factor (aFGF) is a promising regulator of glucose with no adverse effects of hypoglycaemia. Previous researches revealed that aFGF mediated adipose tissue remodeling and insulin sensitivity. These findings supported rh-aFGF135 would be used as a new candidate for the treatment of insulin resistance and type 2 diabetes. In this study, we aimed to investigate the hypoglycemic efficacy of recombinant human acidic fibroblast growth factor 135 (rh-aFGF135) with low mitogenic in type 2 diabetic ZDF rats. ZDF rats were treated with rh-aFGF135 at a daily dosage of 0.25 and 0.50 mg/kg by tail intravenous injection for 5 weeks. The blood glucose levels, oral glucose tolerance test, insulin tolerance test, HOMA-IR for insulin resistance, serum biochemical parameters and the histopathological changes of adipose tissue, liver and other organs were detected at designed time point. The glucose uptake activity and anti-insulin resistance effect of rh-aFGF135 were also detected in HepG2 cells. Results revealed that rh-aFGF135 exhibited a better hypoglycemic effect compared with vehicle group and without the adverse effect of hypoglycaemia in ZDF rats. Compared with vehicle group, rh-aFGF135 significantly improved the situation of hyperglycemia and insulin resistance. Rh-aFGF135 decreased ALT, AST, GSP and FFA levels noticeably compared with vehicle control group (P< 0.01 or P< 0.001). After 5 weeks of treatment, high-dosage rh-aFGF135 could remodel adipose tissue, and has no influence on other organs. H&E staining showed that rh-aFGF135 reduced the size of adipocytes. In addition, rh-aFGF135 may improve insulin resistance partly by increasing the protein expression of p-IRS-1 (human Ser 307). As a hypoglycemic drug for long-term treatment, rh-aFGF135 would be a potentially safe candidate for the therapy of type 2 diabetes.Funding Information
- National Natural Science Foundation of China (81601695)
- Wenzhou Municipal Science and Technology Bureau
This publication has 27 references indexed in Scilit:
- Ellagic acid ameliorates oxidative stress and insulin resistance in high glucose-treated HepG2 cells via miR-223/keap1-Nrf2 pathwayBiomedicine & Pharmacotherapy, 2018
- Increased circulating cell-free DNA in insulin resistanceDiabetes & Metabolism, 2018
- Diagnosis and classification of autoimmune diabetes mellitusAutoimmunity Reviews, 2014
- Global estimates of diabetes prevalence for 2013 and projections for 2035Diabetes Research and Clinical Practice, 2014
- Role of thiazolidinediones, insulin sensitizers, in non‐alcoholic fatty liver diseaseJournal of Diabetes Investigation, 2013
- Regulation of insulin sensitivity by serine/threonine phosphorylation of insulin receptor substrate proteins IRS1 and IRS2Diabetologia, 2012
- The FGF family: biology, pathophysiology and therapyNature Reviews Drug Discovery, 2009
- Attenuation of Insulin-stimulated Insulin Receptor Substrate-1 Serine 307 Phosphorylation in Insulin Resistance of Type 2 DiabetesOnline Journal of Public Health Informatics, 2005
- Nutrient-dependent and Insulin-stimulated Phosphorylation of Insulin Receptor Substrate-1 on Serine 302 Correlates with Increased Insulin SignalingOnline Journal of Public Health Informatics, 2004
- Brain-Derived Acidic Fibroblast Growth Factor: Complete Amino Acid Sequence and HomologiesScience, 1985